ERAS Impact on Return to Treatment in Ovarian Cancer with Kevin Elias

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Kevin Elias to discuss the ERAS impact on return to treatment in ovarian cancer. Kevin Elias is an Assistant Professor of Gynecologic Oncology and Director of the Gynecologic Oncology Laboratory at Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Harvard Medical School. He is the President-Elect of ERAS USA, the American chapter of the ERAS Society. Highlights A. ERAS is associated with shorter lengths of stay and fewer complications for patients undergoing cytoreductive surgery. B. The benefits of ERAS seem to extend beyond the hospital stay, as ERAS is strongly associated with timely resumption of adjuvant chemotherapy. C. Auditing ERAS compliance is a key part of implementing an ERAS pathtway. D. ERAS reduces variation in the quality of patient care, which improves consistency in oncologic treatments and potentially outcomes.